Neoadjuvant Immunotherapy Improves Treatment for Early Resectable Non-Small-Cell Lung Cancer: A Systematic Review and Meta-analysis

Figure 9

Subgroup analysis based on the type for (a) MPR, (b) pCR, (c) the incidence of TRAE, (d) grade 3 or higher TRAEs, (e) surgical resection rate, and (f) incidence of surgical complication.

(a)

(b)

(c)

(d)

(e)

(f)